WO1989008117A1 - Chromatographie par bi-affinite de l'heparine et du cuivre des facteurs de croissance du fibroblaste - Google Patents
Chromatographie par bi-affinite de l'heparine et du cuivre des facteurs de croissance du fibroblaste Download PDFInfo
- Publication number
- WO1989008117A1 WO1989008117A1 PCT/US1988/000587 US8800587W WO8908117A1 WO 1989008117 A1 WO1989008117 A1 WO 1989008117A1 US 8800587 W US8800587 W US 8800587W WO 8908117 A1 WO8908117 A1 WO 8908117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heparin
- eluate
- column
- copper
- contacting
- Prior art date
Links
- 229910052802 copper Inorganic materials 0.000 title claims abstract description 55
- 239000010949 copper Substances 0.000 title claims abstract description 55
- 102000018233 Fibroblast Growth Factor Human genes 0.000 title claims abstract description 18
- 108050007372 Fibroblast Growth Factor Proteins 0.000 title claims abstract description 18
- 238000001042 affinity chromatography Methods 0.000 title abstract description 16
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229960002897 heparin Drugs 0.000 claims abstract description 52
- 229920000669 heparin Polymers 0.000 claims abstract description 52
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 97
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 89
- 150000001875 compounds Chemical class 0.000 claims description 73
- 239000011780 sodium chloride Substances 0.000 claims description 49
- 239000003446 ligand Substances 0.000 claims description 39
- 229920002684 Sepharose Polymers 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000003102 growth factor Substances 0.000 claims description 13
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 239000012501 chromatography medium Substances 0.000 claims description 8
- 150000002460 imidazoles Chemical class 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000012266 salt solution Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000003993 interaction Effects 0.000 abstract description 3
- 101150021185 FGF gene Proteins 0.000 description 46
- 239000000523 sample Substances 0.000 description 20
- 241000894007 species Species 0.000 description 14
- 239000000463 material Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 8
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 238000010828 elution Methods 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 108010034748 copper-binding protein Proteins 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000022382 heparin binding proteins Human genes 0.000 description 2
- 108091012216 heparin binding proteins Proteins 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- FAAYDFBUMOADEP-UHFFFAOYSA-N 3-(2,5-dioxopyrrol-1-yl)-3-hexanoyl-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1C=CC(=O)N1C1(C(=O)CCCCC)CC(=O)N(O)C1=O FAAYDFBUMOADEP-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- -1 biological molecules Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
Definitions
- This invention relates to methods for separating, purifying and/or identifying a compound from a sample, where the compound has an affinity for at least two ligands.
- the method hereinafter referred to as "bi-affinity chromatography", is particularly useful for the separation, identification and purification of species of fibroblast growth factor through use of a heparin-copper bi-affinity chromatography column.
- Affinity chromatography is a well known process which enables the efficient isolation of biological macromolecules or biopolymers by making use of a feature unique to these substances.
- biopolymers such as enzymes and antibodies are capable" of recognizing certain chemical structures with a high degree of selectivity and then binding to them.
- the process of affinity chromatography typically involves a selective adsorbent which is placed in contact with a solution containing several kinds of substances including the desired species, the ligate. The ligate is selectively adsorbed to the ligand, which is attached to an insoluble support or matrix. The nonbinding species are removed by washing. The ligate is then recovered by eluting with a specific desorbing agent.
- endothelial cell locomotion and proliferation were major components of angiogenesis led to the isolation and purification of angiogenic factors.
- endothelial cell growth factors also referred to as endothelial cell growth factors
- FGFs fibroblast growth factor
- bFGF basic fibroblast growth factor
- aFGF acidic fibroblast growth factor
- Fibroblast growth factors which have a broad spectrum of target cells in culture have been reported to induce vascular growth (angiogenesis) in vivo (Esch et al. Proc. Natl. Acad. Sci. U.S.A. 82, 6507-6511 (1985)), Thomas et al. Proc. Natl. Acad Sci. U.S.A. 82, 6409-6413 (1985)).
- FGFs FGFs to heparin might be copper-dependent (Folkman et al., Science 235, 442-447 (1987)) .
- ceruloplasmin and heparin become angiogenic when complexed to copper, but not when deprived of copper (Raju et al. Cancer Res. 44, 1579-1584 (1984)); and (iv) heparin can act as a copper chelator (Grushka et al. Analvt. Lett. 15, 1277-1288 (1982)) and Stivala et al. Fed. Proc. 36, 83-88, (1977)).
- the method comprises the steps of (a) contacting the sample with a bi-affinity column comprising two ligands for which the compound of interest has affinity, (b) contacting the column with an eluate which elutes compounds which do not bind to at least one of the two ligands, and (c) contacting the column with an eluate which elutes compounds which have affinity for both of the ligands.
- the method of the present invention has been particularly useful in the separation, identification and purification of various forms or species of fibroblast growth factors in a simple, rapid manner based on the interaction of these growth factors with heparin and copper.
- the method for separating, identifying and purifying the various forms or species of FGFs comprises contacting a sample containing FGFs with a bi-affinity chromatography column comprising (i) heparin-Sepharose and (ii) a copper-saturated chelating-Sepharose, both commercially available from Pharmacia AB, Uppsala, Sweden.
- the column is thereafter alternately rinsed with (A) an eluate, such as a concentrated salt solution, which will remove compounds which removably bind to heparin, but not to copper; and (B) an eluate which will remove compounds which removably bind to copper, but not to heparin, e.g.
- the FGF proteins which have affinity to both heparin and copper, are removed from the column by elution with an eluant which will remove such proteins from both the heparin and copper binding sites.
- the eluate contains a combination of materials, which serve to remove the proteins from both the heparin and the copper, depending on the concentration of the materials in the eluate.
- the eluate used to remove the FGF's from the column is a linear NaCl/imidazole gradient. Fractions eluted from the column are collected, analyzed and characterized as to their molecular weight, acidic or basic nature and other properties of interest.
- FGFs may have separate binding sites for copper and for heparin.
- a sample containing FGFs is contacted with a bi-affinity column containing both heparin and copper on the chromatography media
- treatment of the column singly with an eluate which would remove the FGF's from a chromatographic media containing heparin, or with an eluate which would remove the FGF's from a chromatographic media containing copper, leaves FGF's on the bi-affinity heparin/copper media.
- the right eluate is applied, e.g. an increasing concentration gradient of both NaCl and imidazole, not only are FGF's removed from the column, but they are clearly separated in accordance with type (aFGF, bFGF) and size.
- the present invention permits resolution of the various multiple forms of
- FGFs based upon bi-affinity chromatography.
- Figure 1 is a schematic illustration of a heparin/copper bi-affinity chromatography column useful in the separation, purification and identification of fibroblast growth factors.
- FIG. 2 illustrates application of heparin/copper bi-affinity chromatography to a sample isolated from bovine hypothalmi.
- Fig. 2A shows the presence and activity of various species of FGFs collected in fractions 6 - 20.
- the inset to Fig. 2A is a depiction of a silver stained gel showing the protein profile prior to heparin/copper bi-affinity chromatography.
- Fig. 2B is depiction of the silver stained fractions collected in Fig. 2A, which samples were previously subjected to SDS gel electrophoresis.
- Fig. 2C and 2D are Western blots of the fractions probed with antibodies raised against basic FGF and acidic FGF respectively. DETAILED DESCRIPTION OF THE INVENTION
- the method comprises contacting a sample containing the compound of interest with a bi—affinity column comprising two ligands to which the compound releasably binds.
- the column is then contacted with a first eluate which elutes those compounds which releasably bind to one of the two ligands.
- the column is thereafter contacted with a second eluate which elutes compounds which releasably bind to the other ligand.
- this process is continued in an alternating fashion for a sufficient number of times until the undesirable components of the sample have been removed.
- the compound of interest is then recovered by contacting the column with an eluate which elutes compounds which releasably bind to both ligands.
- TPA tissue plasminogen activator
- such compounds can be separated, purified and/or identified by (i) contacting a sample containing the compound of interest with a bi-affinity column comprising both ligands to which the compound has an affinity, (ii) alternately contacting the column with eluates which elute compounds which bind to one ligand but not the other, and (iii) contacting the column with an eluate which elutes compounds which have an affinity for both ligands.
- the eluates which may be used in practicing the present invention will vary depending on the compound of interest, and more particularly on the ligands used to construct the bi-affinity column.
- the eluate used should be one which releases the compound of interest from the metal without breaking the bond between the metal and the matrix used to support the metal.
- Weak chelating agents such as imidazole may be used where the matrix is a metal saturated chelating resin such as Pharmacia's chelating-sepharose.
- the alternate eluate used will be a strong ionic solution such as NaCl.
- the eluates chosen will depend on the ligands used to construct the bi-affinity column as well as the relative affinity of those ligands for the compound of interest. Recovery of the compound from the column may be achieved with a gradient of the eluates used in the alternate eluting steps. Fractions are then collected and analysed for the compound of interest.
- the method of the present invention has been particularly useful in the separation, identification and purification of FGFs.
- the method preferably comprises the steps of: (i) contacting a sample containing FGFs with a bi-affinity column comprising heparin and copper on a suitable support; and (ii) eluting the species of FGFs with a suitable eluate such as an increasing concentration gradient of materials which are effective to remove the FGF's from the heparin and the copper.
- a suitable eluate such as an increasing concentration gradient of materials which are effective to remove the FGF's from the heparin and the copper.
- the column is rinsed singly with eluates for heparin-binding proteins and for copper-binding proteins prior to the elution of the FGF's themselves.
- the method also involves collecting fractions containing the separated species of FGFs.
- the heparin and copper components of the bi-affinity column are preferably in the form of a •mixture or blend of heparin-Sepharose (Pharmacia Fine Chemicals, Sweden) and a copper-saturated chelating-Sepharose (Pharmacia Fine Chemicals, Sweden) , although other suitable heparin-resins such as heparin-agarose (Sigma) and chelating-resins such as iminodiacetic acid-agarose (Sigma) may be used in lieu thereof.
- the chromatographic media is preferably constituted so that the number of available heparin-binding sites is approximately equal to the number of available copper-binding sites.
- the ratio by weight percent of heparin-Sepharose to the copper-saturated chelating-Sepharose is preferably from about 10:1 to about 1:10, and most preferably about 1:1.
- the eluates used in connection with this invention will vary depending on the compound of interest.
- the eluate should not contain materials which react unfavorably with the chromatography medium involved, or with the compounds sought to be recovered.
- such eluates will normally be aqueous solutions containing physiological salt and suitable buffering materials to maintain the pH at around 7.
- the preferred buffering composition is Tris, in a concentration of about 10 mM.
- Preferred eluates for eluting heparin-binding proteins from the column comprise salt solutions, e.g. halides of metals of group 1 or 2 of the periodic table of the elements. NaCl is most preferred, and it can be used in increasing concentration gradients, or in varying concentrations, depending upon the usage and the materials to be eluted.
- Other suitable eluates include sulfates such as (NH 4 ) 2 S0 4 .
- Preferred eluates for eluting copper-binding proteins from the column comprise solutions containing materials, generally organic materials, which have a greater affinity for the metal component in the chromatographic media than the proteins to be eluted so that the materials to be eluted are displaced from their association with the metal without interfering with the bond between the metal and the supporting resin.
- Imidazole is preferred, and can be used in increasing concentration gradients, or in varying concentrations, depending upon the usage and the materials to be eluted.
- the bi-affinity column is pre-equilibrated with an appropriate solution in which the compound of interest is stable, for example for
- FGF a 1 to 3M NaCl, 10 mM Tris, pH 7.
- Pre-equilibriation helps to reduce the undesirable sticking of other components of the sample to the ligands used in the bi-affinity column.
- Eluates, reactants and other solutions which come in contact with the compound of interest should also contain suitable buffers and other ingredients in order to avoid undesirable changes in the structure or function of the compound.
- Samples which contain the compound of interest to be separated, identified or purified are preferably partially purified prior to contact with the bi-affinity column of the present invention by, for example, batchwise adsorption to a conventional affinity chromatography column containing a ligand known to bind to that compound. This partial purification helps to prevent overloading of the bi-affinity column with contaminants or other undesirable components of the sample.
- the partially purified sample is applied directly to the pre-equilibrated bi-affinity column.
- the column is thereafter consecutively rinsed with, depending on the size of the column, from about 100 to about 200 ml volumes of one or more eluates to remove materials from the column other than those which bind to both ligands.
- the consecutive rinses comprise alternating rinses in 10 mM Tris, pH 7 of: a 2.0 to 2.5 M NaCl solution and a 10.0 to 20.0 mM solution of imidazole with intervening rinses of a 0.1 to 0.6 M NaCl solution.
- the column is consecutively rinsed with (i) a 2 M NaCl solution, (ii) a 0.6 M NaCl solution, (iii) a 0.6 M NaCl plus a 10 mM imidazole solution, and (iv) a 0.6 M NaCl solution.
- Rinse (i) is to remove those components of the sample which bind to heparin, but not to copper.
- Rinse (ii) is to re-equilibrate the column to allow the protein of interest to bind back to the other ligand, i.e. heparin.
- Rinse (iii) is to remove those components of the sample which bind to copper, but not to heparin.
- Rinse (iv) is to again re-equilibrate the column prior to the ultimate elution of the protein of interest.
- all of rinses (i) through (iv) would tend to remove materials or contaminants which were not bound to heparin, copper or some other component of the chromatography media.
- the FGFs are eluted with an appropriate eluting gradient such as an NaCl/imidazole gradient.
- the NaCl/imidazole gradient preferably comprises a 0 to 0.6 M NaCl without imidazole to a 2 to 3 M NaCl plus a 10 to 20 mM imidazole at a pH of about 7.
- the volume of the gradient depends on the size of the column employed.
- the NaCl/imidazole gradient comprises about 100 ml of 0.6 M NaCl without imidazole to about 100 ml of 2 M NaCl plus 10 mM imidizole at a pH of about 7.
- imidazole is increasing in concentration from 0 to 10 mM
- NaCl is increasing in concentration from 0.6 to 2 M.
- the source of the sample e.g. brain vs.
- this gradient can be optimized by changing the imidazole and NaCl concentrations to improve separation of the various species of FGF present in the particular sample.
- the flow rate of the eluents will vary depending on a number of factors, including the size of the column. In general, for a 1 cm x 9 cm column containing 7.0 ml of the heparin and copper components, the flow rate is between about 10 ml/hr and about 40 ml/hr, preferably between about 15 ml/hr and 30 ml/hr, and most preferably about 20 ml/hr.
- the volume of fractions collected from the column will also vary depending on a number of factors including the resolving power of the column. That is, the greater the resolving power, the greater the fraction that can be collected. In general, for the above described column, the volume of fractions collected is between about 2 and 10 ml, preferably between about 3 and 7 ml, and most preferably about 5 ml.
- fractions eluted from the bi-affinity column in accordance with the present invention may be analyzed by a number of methods to confirm resolution of the compound of interest from the original sample.
- analytical techniques include analysis of mitogenic activity, e.g., by measuring uptake of tritiated thymidine by quiescent confluent monolayers of BALB/c mouse 3t3 cells, as described in Klagsbrun et al., Proc. Natl. Acad. Sci. U.S.A. 82, 805-809 (1985)), the disclosure of which is incorporated herein by reference.
- Bovine hypothalami 100 g obtained from Pel-Freez (Rogers, Arkansas) were homogenized in 300 ml of 0.15 M (NH 4 ) 2 S0 4 at pH 6 and extracted by stirring at 4°C for 2 hours.
- the crude extract was centrifuged at 15,000 X g for 1 hour and the supernatant solution was loaded directly onto a heparin-Sepharose column (1.5 cm X 12 cm) pre-equilibrated with 0.6 M NaCl in 10 mM Tris, pH 7.
- the column was rinsed with 300 ml of 0.6 M NaCl in 10 mM Tris, pH 7.
- a sample of crude extract containing FGFs were substantially eluted with 40 ml of 2 M NaCl in the same buffer.
- bovine fibroblast growth factor activity About 7 x 10 5 units of bovine fibroblast growth factor activity were extracted from bovine hypothalmi. More than 95% of this activity bound to heparin-sepharose in 0.6 M NaCl and could be eluted with 2 M NaCl as described below.
- Copper-saturated chelating-Sepharose component was prepared by adding 100 ml of 2 mg/ml copper (II) chloride to 50 ml of chelating-Sepharose (Pharmacia) , followed by several gentle mixings over a one-hour period and decanting.
- a heparin-copper bi-affinity column was prepared by thoroughly mixing 3.5 ml each of heparin-Sepharose (Pharmacia) and copper-Sepharose, and placing the mixture in a 7.0 ml column (1 cm x 9 cm) . The mixture was blue in appearance.
- the sample (40 ml) of FGF which was partially purified by batchwise • adsorption to heparin-Sepharose as described above, was applied directly to this blue color bi-affinity column which had been pre-equilibrated with 2 M NaCl, 10 mM Tris, pH 7.
- the column was rinsed consecutively with 40 ml each of the following reagents, all in 10 mM Tris, pH 7: (i) 2 M NaCl, (ii) 0.6 M NaCl, (iii) 0.6 M NaCl plus 10 mM imidazole, (iv) 0.6 M NaCl.
- FGFs were eluted at a flow rate of 20 ml/hr with a linear NaCl/imidazole gradient from 100 ml of 0.6 M NaCl without imidazole to 100 ml of 2 M NaCl plus 10 mM imidazole in 10 mM Tris, pH 7. Fractions (10 ml) were collected and assayed for growth factor activity.
- growth factor activity was detected starting at about fraction No. 9, which corresponded to eluate containing about 1.3 M NaCl and 5 mM imidazole. About 30% of the initial growth factor activity as recovered. FGF activity was assessed by measuring the incorporation of [ 3 H]thymidine into the DNA of quiescent, confluent monolayers of BALB/c mouse 3T3 cells in 96-well plates as previously described (Klagsbrun et al. Proc. Natl. Acad. Sci. U.S.A. 82, 805-809 (1985)).
- One unit of activity was defined as the amount of growth factor required to stimulate half-maximal DNA synthesis in 3T3 cells (about 10,000 cells per 0.25 ml of growth medium per well) .
- protein concentration was estimated by the method of Lowry et al. (Lowry et al. J. Biol. Chem. 193, 265-275 (1951)) .
- Rabbits were injected at multiple dorsal intradermal sites with 500 ug each of KLH-peptide conjugate emulsified with complete Freund's adjuvant. Animals were boosted regularly at 3-6 weeks intervals with 200 ug of KLH peptide conjugated emulsified in incomplete Fruend's adjuvant. The titer of the antisera after the second booster injection was about 1:15,000 to 1:50,000 as determined in an ELISA using unconjugated peptide as the antigen.
- nitrocellulose sheet was incubated with antiserum against either bFGF or aFGF and visualized by successive incubations with biotinylated goat anti-rabbit IgG, streptavidin-biotinylated peroxidase complex, and enzyme substrate (4-chloro-l-naphthol) until color develops (Nakane et al. J. Histoche . Cvtochem. 16, 557-560 (1968)).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Méthodes de séparation, d'identification et de purification de diverses formes de facteurs de croissance du fibroblaste, suivant une nouvelle technique de chromatographie par bi-affinité, basée sur l'interaction des facteurs de croissance du fibroblaste avec l'héparine et le cuivre.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1988/000587 WO1989008117A1 (fr) | 1988-02-24 | 1988-02-24 | Chromatographie par bi-affinite de l'heparine et du cuivre des facteurs de croissance du fibroblaste |
PCT/US1988/001660 WO1989008144A1 (fr) | 1988-02-24 | 1988-05-17 | Chromatogrophie par bi-affinite de composes presentant une affinite pour deux ou plusieurs ligands |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1988/000587 WO1989008117A1 (fr) | 1988-02-24 | 1988-02-24 | Chromatographie par bi-affinite de l'heparine et du cuivre des facteurs de croissance du fibroblaste |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989008117A1 true WO1989008117A1 (fr) | 1989-09-08 |
Family
ID=22208560
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/000587 WO1989008117A1 (fr) | 1988-02-24 | 1988-02-24 | Chromatographie par bi-affinite de l'heparine et du cuivre des facteurs de croissance du fibroblaste |
PCT/US1988/001660 WO1989008144A1 (fr) | 1988-02-24 | 1988-05-17 | Chromatogrophie par bi-affinite de composes presentant une affinite pour deux ou plusieurs ligands |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/001660 WO1989008144A1 (fr) | 1988-02-24 | 1988-05-17 | Chromatogrophie par bi-affinite de composes presentant une affinite pour deux ou plusieurs ligands |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO1989008117A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015504A1 (fr) * | 1990-04-04 | 1991-10-17 | Sciosnova Inc. | Procede de purification de facteur de croissance de fibroblaste de base |
US5192312A (en) * | 1991-03-05 | 1993-03-09 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
US5331095A (en) * | 1993-04-12 | 1994-07-19 | Scios Nova Inc. | Process for purification of basic fibroblast growth factor |
US5613982A (en) * | 1994-03-14 | 1997-03-25 | Cryolife, Inc. | Method of preparing transplant tissue to reduce immunogenicity upon implantation |
-
1988
- 1988-02-24 WO PCT/US1988/000587 patent/WO1989008117A1/fr unknown
- 1988-05-17 WO PCT/US1988/001660 patent/WO1989008144A1/fr unknown
Non-Patent Citations (4)
Title |
---|
BIOCHEM. BIOPHYS. RES. COMMUN., Vol. 142, No. 2, Published 31 January 1987, by ACADEMIC PRESS, INC. (NEW YORK, NEW YORK, USA), A. BAIRD et al., "Fibroblast Growth Factors are Present in the Extracellular Matrix Produced by Endothelial Cells In Vitro: Implications for a Role of Heparinase Like Enzymes in the Neovascular Response", pages 428-435. * |
BIOCHEM. BIOPHYS. RES. COMMUN., Vol. 146, No. 2, Published 31 July 1987, by ACADEMIC PRESS INC. (NEW YORK, NEW YORK, USA), M. IWANE et al., "Expression of cDNA Encoding Human Basic Fibroblast Growth Factor in E. Coli", pages 470-477. * |
BIOCHEMISTRY, Vol. 25, No. 21, Published 21 October 1986, by AMERICAN CHEMICAL SOCIETY (WASHINGTON, D.C.), J.M. ROWE et al., "Purification and Characterization of a Human Pituitary Growth Factor", pages 6421-6425. * |
PROC. NATL. ACAD. SCI. U.S.A., Vol. 83, Published October 1986, by NATIONAL ACADEMY OF SCIENCES (WASHINGTON, D.C. USA), R. MIRA-Y-LOPEZ et al., "Identification of a Pituitary Factor Responsible for Enchancement of Plasminogen Activator Activity in Breast Tumor Cells", pages 7780-7784. * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015504A1 (fr) * | 1990-04-04 | 1991-10-17 | Sciosnova Inc. | Procede de purification de facteur de croissance de fibroblaste de base |
US5136025A (en) * | 1990-04-04 | 1992-08-04 | California Biotechnology Inc. | Method to purify basic fibroblast growth factor |
US5192312A (en) * | 1991-03-05 | 1993-03-09 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
US5772695A (en) * | 1991-03-05 | 1998-06-30 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
US5855617A (en) * | 1991-03-05 | 1999-01-05 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
US5863296A (en) * | 1991-03-05 | 1999-01-26 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
US5331095A (en) * | 1993-04-12 | 1994-07-19 | Scios Nova Inc. | Process for purification of basic fibroblast growth factor |
US5613982A (en) * | 1994-03-14 | 1997-03-25 | Cryolife, Inc. | Method of preparing transplant tissue to reduce immunogenicity upon implantation |
US5632778A (en) * | 1994-03-14 | 1997-05-27 | Cryolife, Inc. | Treated tissue for implantation and methods of preparation |
US5843182A (en) * | 1994-03-14 | 1998-12-01 | Cryolife, Inc. | Treated tissue for implantation and methods of preparation |
US5899936A (en) * | 1994-03-14 | 1999-05-04 | Cryolife, Inc. | Treated tissue for implantation and methods of preparation |
Also Published As
Publication number | Publication date |
---|---|
WO1989008144A1 (fr) | 1989-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shing | Heparin-copper biaffinity chromatography of fibroblast growth factors. | |
Iyengar et al. | The complete amino‐acid sequence of the sweet protein thaumatin I | |
Lobb et al. | Purification of two distinct growth factors from bovine neural tissue by heparin affinity chromatography | |
Böhlen et al. | Human brain fibroblast growth factor: Isolation and partial chemical characterization | |
JPH11509314A (ja) | 高速自動化連続流、多次元分子選別および分析 | |
Huhtala et al. | Biologically active domain in somatomedin-binding protein | |
Baglia et al. | Localization of the high molecular weight kininogen binding site in the heavy chain of human factor XI to amino acids phenylalanine 56 through serine 86. | |
Takahashi et al. | Application of an automated tandem high-performance liquid chromatographic system to peptide mapping of genetic variants of human serum albumin | |
Settleman et al. | Chromogranin, an integral membrane protein. | |
US6207807B1 (en) | Method for the separation and purification of immunoglobulins | |
Heegaard et al. | Demonstration of a heparin-binding site in serum amyloid P component using affinity capillary electrophoresis as an adjunct technique | |
WO1989008117A1 (fr) | Chromatographie par bi-affinite de l'heparine et du cuivre des facteurs de croissance du fibroblaste | |
Stathakis et al. | Human fibrinogen heterogeneities. Preparation and characterization of γ and γ′ chains | |
SCHOLZ et al. | Low‐Molecular‐Weight Polypeptides of Vicilin from Vicia faba L. are Product of Proteolytic Breakdown | |
EP0411503B1 (fr) | Procédé pour l'identification et la synthèse des sites de liaison de protéines interagissants | |
Righetti et al. | The “Invisible Proteome”: How to capture the low-abundance proteins via combinatorial ligand libraries | |
Eurell et al. | Purification of swine haptoglobin by affinity chromatography. | |
DE69613086T2 (de) | Antigenen Peptide mit Glycinsubstitution | |
Chashchin et al. | The domain structure of the cholesterol side-chain cleavage cytochrome P-450 from bovine adrenocortical mitochondria: localization of HAEM group and domains in the polypeptide chain | |
Wilson et al. | Chromogranin from normal human adrenal glands: purification by monoclonal antibody affinity chromatography and partial N-terminal amino acid sequence | |
EP0241830A2 (fr) | Facteur de croissance, dérivé d'hépatomes | |
JPH03233356A (ja) | 2もしくはそれ以上のリガンドに対し親和性を有する化合物のバイアフィニティクロマトグラフィー | |
Chawla et al. | Cancer‐Related urinary proteinase inhibitor, EDC1: A new method for its isolation and evidence for multiple forms | |
Li et al. | A simple and rapid method for isolating small myotoxins from rattlesnake venoms | |
Högenauer et al. | Isolation and characterization of blood clotting factors VII and X |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |